The Tachycardia (Tachyarrhythmias) drugs in development market research report provides comprehensive information on the therapeutics under development for Tachycardia (Tachyarrhythmias), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tachycardia (Tachyarrhythmias). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tachycardia (Tachyarrhythmias) and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Tachycardia (Tachyarrhythmias) by 14 companies/universities/institutes. The top development phase for Tachycardia (Tachyarrhythmias) is preclinical with six drugs in that stage. The Tachycardia (Tachyarrhythmias) pipeline has 13 drugs in development by companies and two by universities/ institutes. Some of the companies in the Tachycardia (Tachyarrhythmias) pipeline products market are: ARMGO Pharma, Cardurion Pharmaceuticals and GEXVal.
The key targets in the Tachycardia (Tachyarrhythmias) pipeline products market include Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1), Calcium Channel, and Calcium/Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17).
The key mechanisms of action in the Tachycardia (Tachyarrhythmias) pipeline product include Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist with three drugs in Filing rejected/Withdrawn. The Tachycardia (Tachyarrhythmias) pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Tachycardia (Tachyarrhythmias) pipeline products market including Small Molecule, and Gene Therapy.
Tachycardia (Tachyarrhythmias) overview
Tachycardia also known as tachyarrhythmias is a condition where heartbeats >100 beats per minute, which is faster than normal heartbeat. Tachycardia is commonly observed during running, exercise, shock, or anxious cases but it is a concern when occurring at rest. There are 3 types of tachycardia which are sinus, ventricular and supraventricular. Sinus tachycardia commonly occurs after a strenuous exercise, in supraventricular tachycardia occurs in the upper chamber while in ventricular in the lower chambers all these 3 conditions result in rapid heartbeat. Pathologically it occurs because of cardiac problems or non-cardiac most commonly hypoxia, pulmonary emboli, dehydration, hypoglycemia, infectious diseases, hematologic and vascular, drug toxicity. Diagnosed by 2D echo, ECG, and other required radiographic and laboratory examinations. Patients are presented with SOB, fatigue, sudden fainting, palpitations, dizziness. Treating the underlying conditions is the only way for this condition followed by non-pharmacological methods like having healthy diet, preventing strenuous exercise.
For a complete picture of Tachycardia (Tachyarrhythmias)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
